Accès ouvert · CC BY

Anti-PRL-3 Monoclonal Antibody inhibits the Growth and Metastasis of colorectal adenocarcinoma

Article scientifique 2023 Sciences de la vie et biotechnologies › Biotechnologies (OCDE 2.9) Anglais

Résumé

Background: Colon cancer is the one of leading causes of cancer-related death.Chemotherapy, radiotherapy and immunotherapy will be the mainstream in inoperable advanced cancer in clinics.Precision treatment is still lack in colon cancer. Materials and Methods:We developed a series of mAbs targeting PRL-3 through different types of immunogens.The binding domains of mAbs were identified through the ELISA and Western blotting experiments.The antitumor activity of mAbs was verified by cell proliferation, migration and invasion experiments.Xenograft subcutaneous and metastatic models and patient derived Xenograft (PDX) model were established.Results: mAb 12G12 targeting 77-120AA exhibited inhibition in migration and invasion experiments.12G12 inhibited the migration of multiple types of cancer cells, including colon cancer, gastric cancer, esophagus cancer, liver cancer, lung cancer and pancreatic cancer cells.12G12 decreased the tumor growth and metastasis in Xenograft subcutaneous and metastatic tumor model, respectively.The antitumor activity of mAb 12G12 was also confirmed in PDX model of gastric cancer.PRL-3 interacted with Golgi protein TMED10.Knockdown of TMED10 expression attenuated the cell migration triggered by purified GST-PRL-3 protein.Conclusion: Our results confirmed the antitumor activity of mAb 12G12 in colorectal adenocarcinoma and provided a new potential targeted therapy of colon cancer.

Citer ce document

Sun, S., Meng, L., Xing, X., Li, N., Song, Q., Qiao, D., Qu, L., Liu, C., An, G., Li, Z., Shou, C., & Lian, S. (2023). Anti-PRL-3 Monoclonal Antibody inhibits the Growth and Metastasis of colorectal adenocarcinoma. Journal of Cancer. https://doi.org/10.7150/jca.81702

Exporter : BibTeX · RIS (Zotero, Mendeley, EndNote)

Accès au document

Texte intégral archivé sur SPHAERO, en accès ouvert : lisible gratuitement en ligne après connexion. Le document reste aussi disponible à sa source. Se connecter

Voir l'article sur le site de la revue

Licence et provenance

Licence : CC BY

Notice moissonnée depuis OpenAlex le 10/09/2026. Le document reste hébergé par sa source.
Voir le document à la source →

Statistiques

Consultations (hors robots) : 14

Téléchargements (hors robots) : 0

Méthode de comptage